Medicine
Vyalev 120 mg/2400 mg per 10 mL injection
Vyalev 120 mg/2400 mg per 10 mL injection is a prescription medicine containing Foscarbidopa and Foslevodopa for subcutaneous use, marketed by AbbVie, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store VYALEV refrigerated at 2°C to 8°C (36°F to 46°F). Once VYALEV has been…
Key facts
- Active ingredient (INN)
- Foscarbidopa and Foslevodopa
- Brand
- Vyalev
- Strength
- 120 mg/2400 mg per 10 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 7 vials of 10 mL
- Marketing authorisation holder
- AbbVie
- Manufacturer
- AbbVie
- Origin register
- US FDA, United States
- Storage
- Store VYALEV refrigerated at 2°C to 8°C (36°F to 46°F). Once VYALEV has been stored at room temperature, do not return the product to the refrigerator. Do not freeze. If stored at room temperature, discard VYALEV if not used within 28 days. VYALEV may be stored at room temperature up to a maximum of 30°C (86°F) for a single period of up to 28 days. Do not shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 12 April 2022
- Identifiers
- RxCUI 2695782, 2695789DailyMed set ID 28e806e4-951c-40a9-9f0c-d0929caf054cNDC 0074-0501Application NDA216962
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 7 vial, single-dose in 1 carton / 10 mL in 1 vial, single-dose | 0074-0501-01 | AbbVie | 12 April 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 16 October 2024 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Foscarbidopa and Foslevodopa is a fixed-dose combination medicine indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). It is available as injection for subcutaneous use. MedsAcross supplies Foscarbidopa and Foslevodopa for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Foscarbidopa and FoslevodopaFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Vyalev prescribing information (AbbVie) · U.S. National Library of Medicine, DailyMed
Need Vyalev 120 mg/2400 mg per 10 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.